Company Overview
PMV Pharmaceuticals, Inc. operates as a precision oncology company dedicated to the discovery and development of small molecule therapies that specifically target p53 mutations and other p53-related cancers within the United States. The company functions within the Healthcare sector and the Biotechnology industry, a space characterized by high capital intensity and reliance on successful clinical trial outcomes to achieve commercial viability. This biotechnology firm maintains a market capitalization of $69.86M and employs 54 individuals to advance its research initiatives. The valuation metrics indicate that the company is a micro-cap entity operating with limited revenue recognition to date, as its financial profile is currently defined by significant investment in development rather than established sales streams, which is typical for early-stage biotechnology companies focused on novel therapeutic mechanisms like rezatapopt.
Financial Health
The company reports Net Income (TTM) of $-77,742,000 and EBITDA of $-86,073,000, while Revenue (TTM) is listed as N/A, indicating that current earnings are entirely driven by operational expenses rather than sales. The substantial negative net income relative to the negative EBITDA suggests that the company incurs significant non-operating costs or interest expenses that further erode profitability before reaching the bottom line. Free Cash Flow stands at $-46,936,752, reflecting a burn rate that consumes the company's liquidity as it funds its clinical pipeline and operational overhead. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a status common for pre-revenue biotechnology firms where revenue has not yet been sufficient to calculate traditional profitability ratios. On the balance sheet, the company holds $112.94M in cash against $838,000 in debt, resulting in a Debt to Equity ratio of 0.80, which indicates a relatively low leverage position given the massive cash reserves. The Current Ratio is 10.09, demonstrating an extremely strong short-term liquidity position where current assets vastly exceed current liabilities. Return on Equity is -55.4% and Return on Assets is -35.0%, metrics that reveal management is currently deploying capital to fund growth initiatives rather than generating returns, a standard characteristic of companies in the development phase before product approval.
Valuation Assessment
The P/E Ratio (TTM) is N/A and the Forward P/E is -1.19, implying that traditional earnings-based valuation models are not applicable due to the company's current lack of profitability and negative forward earnings expectations. The Price to Book ratio is 0.67, suggesting that the market values the company at a discount to its book value, which often occurs with biotechnology firms where intangible assets and pipeline potential are not fully captured on the balance sheet. The Price to Sales ratio is N/A and the EV/EBITDA is 0.49, providing an enterprise value multiple that is extremely low, likely reflecting the high risk premium associated with the company's unproven commercial prospects and negative earnings trajectory. The stock has a 52-Week High of $1.88 and a 52-Week Low of $0.81, establishing a trading range of $1.07 where the current market price fluctuates based on clinical data releases and sector sentiment. With a Beta of 1.31, the stock exhibits volatility that is significantly higher than the broader market, meaning price movements will be amplified relative to general market swings. These valuation metrics collectively paint a picture of a high-risk, high-potential asset where traditional valuation multiples are skewed by the company's developmental stage and financial structure.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both N/A, indicating that the company does not yet have a consistent track record of year-over-year expansion to calculate growth rates. Since the company does not pay dividends, the Dividend Yield is N/A and the Payout Ratio is 0.0%, meaning the company retains all earnings to fund its operations and research rather than distributing income to shareholders. The absence of a dividend yield confirms that the company reinvests its entire financial resources, including its $112.94M cash balance, into the development of rezatapopt and other small molecule therapies. The overall growth and income profile is defined entirely by capital deployment for clinical advancement rather than income generation or shareholder distributions, a strategy typical for precision oncology companies in the Phase 2 clinical trial stage.